In a joint white paper, Bureau Veritas and its partner OPTEL outline ways to address the unprecedented challenge of assuring COVID-19 vaccine supply around the world.
Thanks to groundbreaking work by the global healthcare ecosystem, the fastest vaccine rollout in history is underway. Production sites are making COVID-19 vaccines at record speeds, while governments are buying them in never before-seen quantities.
However, while the delivery of doses around the globe has been increasing greatly over the past few weeks, there must be a concurrent ramp-up in terms of supply chain control and monitoring.
Governments face a great imperative to ensure that doses are kept at proper temperatures and arrive on time, at the right location. This requires optimal vaccine traceability and process transparency, which will in turn engender a higher feeling of trust among the public.
In this context, the purpose of this white paper is to:
- Identify gaps in the supply chain and find solutions
- Explore how to ensure a seamless COVID-19 vaccine supply chain
- Introduce V-Trace: a ready-to-use solution for vaccine campaign management and monitoring
Bureau Veritas and OPTEL have partnered to launch V-TRACE, a complete traceability solution for the COVID-19 vaccine throughout the supply chain.
Thanks to this partnership, OPTEL and Bureau Veritas are able to offer a combined expertise that is unrivalled in the pharmaceutical industry and in supply chain assurance.
OUR WHITE PAPER ON THE CHALLENGES OF THE COVID-19 VACCINE SUPPLY
PRESS RELEASE: BV AND OPTEL LAUNCH V-TRACE, A COMPLETE TRACEABILITY SOLUTION FOR COVID-19 VACCINES